Mayne completed agreement for US distribution rights for Generic Nuvaring February 2017. Had acceptance for filing with FDA Mar. 2018 . Announced expected approval 2019. After 2 ( Two ) rejections lay one October 6 2020. They have had 7 months to resubmit but still No. I accept it is best to do it right before submission. Scott Richards was in charge of first two failures and I presume he has now employed someone capable of doing it right. At least I certainly hope so. My worry now is he has obviously proven himself a complete failure in gaining approval of a generic. Is he going to be the same in distribution of Mithras recently approved E4. So far his sales of products has done nothing but slide. The Board of Mayne needs to act with urgency or a disaster May be forthcoming .
MYX Price at posting:
40.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)